Primary Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), By Origin (Human Primary Cells, Animal Primary Cells), By End user (Pharma Biotech, CROS, Academia), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.13 Billion
CAGR (2026-2031)	5.99%
Fastest Growing Segment	Human Primary Cells
Largest Market	North America
Market Size (2031)	USD 3.02 Billion

Market Overview

The Global Primary Cells Market will grow from USD 2.13 Billion in 2025 to USD 3.02 Billion by 2031 at a 5.99% CAGR. The Global Primary Cells Market comprises cells isolated directly from living tissue that maintain the physiological traits of the donor, serving as a superior alternative to immortalized cell lines for in vitro studies. The expansion of this sector is primarily supported by the increasing prevalence of chronic diseases and the growing volume of biopharmaceutical research requiring accurate models for toxicity and efficacy screening. According to the Pharmaceutical Research and Manufacturers of America, in 2024, there were more than 8,000 medicines in clinical development globally. This extensive pipeline directly amplifies the demand for primary cells in preclinical validation phases.

Despite these favorable conditions, the market encounters a substantial impediment regarding the ethical and logistical complexities of tissue sourcing. Obtaining quality human tissue involves stringent regulatory compliance and relies on a finite number of donors, creating supply bottlenecks that may restrict the accessibility of specific cell types for research applications.

Key Market Drivers

The escalating global incidence of cancer and chronic diseases acts as a fundamental catalyst for the market, as researchers increasingly prioritize primary cells to model complex pathologies with greater physiological accuracy than immortalized lines. These biological materials are indispensable for oncology studies, particularly for deciphering tumor microenvironments and evaluating patient-specific drug responses. According to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024', it was projected that 2,001,140 new cancer cases would be diagnosed in the United States alone during the year. This growing disease burden necessitates predictive preclinical models, directly intensifying the acquisition of both healthy and diseased primary tissue for drug discovery and biomarker identification.

Simultaneously, a substantial surge in financial support for cell-based research is fortifying the infrastructure required for advanced screening utilizing primary cells. Capital inflows enable biotechnology entities to scale operations and integrate sophisticated assay platforms that depend on these donor-derived cells for validity. According to the Alliance for Regenerative Medicine, January 2024, in the 'State of the Industry' briefing, the regenerative medicine sector attracted $11.7 billion in global investment throughout 2023. This financial momentum is complemented by high regulatory productivity which drives upstream demand; according to the U.S. Food and Drug Administration, in 2023, the agency approved 55 novel therapeutics, the second-highest annual total in its history. This convergence of capital availability and regulatory activity solidifies the reliance on primary cells to minimize late-stage clinical attrition.

Download Free Sample Report

Key Market Challenges

The ethical and logistical complexities associated with sourcing human tissue significantly constrain the expansion of the global primary cells market. Obtaining high-quality, viable cells requires strict adherence to regulatory frameworks and ethical consent procedures, which often prolongs procurement timelines. Because primary cells must be isolated directly from living tissue, manufacturers rely heavily on a limited pool of suitable donors. This dependency creates unavoidable supply bottlenecks, making it difficult to maintain consistent inventories of specific cell types required for large-scale biopharmaceutical projects.

These shortages directly affect the scalability of research and development operations. When specific cell types are unavailable, timelines for toxicity testing and drug screening are delayed, inevitably increasing operational costs for pharmaceutical companies. The scarcity of donor tissue is a persistent issue affecting the availability of biological materials. According to the Health Resources and Services Administration, in 2024, over 103,000 people were on the national transplant waiting list in the United States, highlighting the critical shortage of organs and tissues available for medical and research use. This widespread gap between the demand for human tissue and the available supply limits the volume of primary cells that can be commercially produced.

Key Market Trends

The Shift Toward Human-Derived Alternatives to Animal Testing is fundamentally restructuring the global primary cells market, driven by intensifying regulatory pressure and public demand for ethically sourced research models. This transition is prioritizing the acquisition of human primary cells to replace animal-derived substrates in toxicology and safety assessment, ensuring greater biological relevance for human health outcomes. The momentum for this ethical realignment is evidenced by substantial civic engagement influencing legislative roadmaps. According to PETA, April 2025, in the 'New Report on Phasing Out Animal Testing in the EU', the European Commission's development of a roadmap to phase out animal testing in chemical safety assessments was directly responsive to a European Citizens' Initiative that secured over 1.2 million verified signatures from the public.

Simultaneously, the Development of Microphysiological Systems Using Primary Cells is creating a critical high-value application for donor-specific tissues, moving beyond simple 2D cultures to complex, organ-mimicking environments. These advanced platforms, or organ-on-chips, rely heavily on high-quality primary cells to replicate physiological functions, offering a solution to the translational gap often seen in traditional preclinical studies. The adoption of these systems is accelerating as pharmaceutical developers seek to mitigate the high attrition rates of drug candidates. According to Pharmaceutical Outsourcing, March 2025, in the article 'Changing Course in 2025 Toward Personalized Healthcare, Drug Development and Reduced Animal Testing', approximately 92% to 96% of drugs that successfully pass animal testing phases subsequently fail in human clinical trials, underscoring the urgent market necessity for these human-centric primary cell models.

Segmental Insights

Human Primary Cells represent the fastest growing segment within the Global Primary Cells Market due to an increasing preference for models derived from humans rather than animals. Researchers prioritize these cells because they offer superior biological relevance, closely mimicking human physiology which improves the prediction of drug safety and efficacy. This transition is further accelerated by initiatives from regulatory bodies such as the U.S. Food and Drug Administration that encourage the adoption of testing methods not involving animals. Consequently, pharmaceutical organizations are extensively utilizing these cells to minimize failures during later clinical stages.

Regional Insights

North America maintains a dominant position in the global primary cells market due to extensive research and development activities in the pharmaceutical and biotechnology sectors. This leadership is supported by significant government funding for life sciences, particularly from institutions like the National Institutes of Health (NIH), which accelerates drug discovery and chronic disease research. Additionally, the region benefits from a high concentration of key industry players and academic research centers that actively utilize primary cells for toxicity testing and regenerative medicine studies. These factors collectively create a favorable environment for sustained market growth across the United States and Canada.

Recent Developments

• In January 2025, Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific announced a strategic collaboration to accelerate the development of cell therapies. This partnership integrated Fujifilm’s T-cell expansion media with Terumo’s automated cell expansion system to create a streamlined, scalable workflow for T-cell manufacturing. The collaboration aimed to address critical challenges in the production of primary immune cells, such as process standardization and scalability, by providing developers with a complete solution that reduces the barriers to entering clinical manufacturing. The General Manager of Global Therapy Innovations at Terumo Blood and Cell Technologies highlighted that the joint offering would advance process consistency and reduce risks in therapy development.
• In October 2024, BioIVT launched a new primary cell product, the LEUKOMAX XL, designed to provide researchers with a significantly higher yield of immune cells from a single donor collection. This fresh leukopak product was developed to offer a minimum of 15 billion total nucleated cells, representing a substantial increase compared to standard full leukopaks. The product aimed to support the growing demand for large-scale cell and gene therapy research by maximizing the number of cells available for downstream processing and characterization. This launch reinforced the company's position as a leading provider of high-quality primary cellular starting materials for the biopharmaceutical industry.
• In April 2024, PromoCell released Cryo-SFM Plus, a new defined, protein-free, and animal component-free cryopreservation medium optimized for primary cells and stem cells. This product was developed to ensure superior cell viability, attachment, and growth performance after thawing, addressing common challenges associated with the freezing of sensitive primary human cells. The launch featured an innovative antioxidant technology designed to minimize freezing damage and maximize cell yield, supporting consistent results in applications such as drug discovery and tissue engineering. The product was made available in both phenol red-containing and phenol red-free formulations to suit various experimental requirements.
• In January 2024, STEMCELL Technologies acquired Propagenix Inc., a biotechnology company focused on developing technologies for the expansion of primary cells. This acquisition provided STEMCELL Technologies with exclusive rights to proprietary technology that enables the massive expansion of primary epithelial cells from various tissues, including the lung, airway, and skin, without the need for feeder cells. The integration of this breakthrough technology into the company's portfolio was intended to empower researchers by providing tools that overcome the limited lifespan and expansion capability of primary cells in culture, thereby facilitating advancements in regenerative medicine and disease modeling.

Key Market Players

• AllCells
• ZenBio Inc.
• PromoCell
• Thermo Fisher Scientific Inc.
• Cell Biologics Inc.
• STEMCELL Technologies Inc.
• Merck KGaA
• American Type Culture Collection (ATCC)

By Product	By Origin	By End user	By Region
Hematopoietic Dermatocytes Hepatocytes Gastrointestinal Lung Renal Heart Musculoskeletal	Human Primary Cells Animal Primary Cells	Pharma Biotech CROS Academia	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Primary Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Primary Cells Market, By Product:

• Hematopoietic
• Dermatocytes
• Hepatocytes
• Gastrointestinal
• Lung
• Renal
• Heart
• Musculoskeletal

• Primary Cells Market, By Origin:

• Human Primary Cells
• Animal Primary Cells

• Primary Cells Market, By End user:

• Pharma Biotech
• CROS
• Academia

• Primary Cells Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE